Warfarin anticoagulation and outcomes in patients with atrial fibrillation - A systematic review and metaanalysis

被引:206
|
作者
Reynolds, MW
Fahrbach, K
Hauch, O
Wygant, G
Estok, R
Cella, C
Nalysnyk, L
机构
[1] MetaWorks Inc, Medford, MA USA
[2] AstraZeneca LP, Wilmington, DE USA
关键词
anticoagulation; atrial fibrillation; warfarin;
D O I
10.1378/chest.126.6.1938
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To examine the relationship between international normalized ratio (INR) and Outcomes (major bleeding events and strokes) in patients with atrial fibrillation (AF) receiving anticoagulation with warfarin. Methods: A systematic review and metaanalysis of studies published in the English language between January 1, 1985, and October 30, 2002, was performed. MEDLINE (PubMed), Current Contents, and relevant reference lists were searched. Studies enrolling patients with nonvalvular AF receiving warfarin anticoagulation were eligible for inclusion if they reported stroke and/or major bleeding events in relation to INR, or time spent in therapeutic range. The risk of bleeds in overanticoagulated patients (INR > 3) and the risk of strokes in underanticoagulated patients (INR < 2) were assessed. Results: Twenty-one studies (6,248 patients) met all inclusion criteria. Of the 21 studies, a target conventional INR of 2 to 3 was used in 9 studies. An INR < 2, compared with an INR : 2, was associated with an odds ratio (OR) for ischemic events of 5.07 (95% confidence interval [CI], 2.92 to 8.80). An INR > 3, compared with an INR :5 3, was associated with an OR for bleeding events of 3.21 (95% CI, 1.24 to 8.28). On average, in the four studies with a target INR range of 2 to 3, patients with AF receiving warfarin spent 61% of time within, 13% of time above, and 26% below the therapeutic range. Conclusion: Available evidence indicates that in patients with nonvalvular AF, the risk of ischemic stroke with insufficient warfarin anticoagulation (INR < 2), and the risk of bleeding events with overanticoagulation (INR > 3) are significantly higher relative to patients with AF maintained within the recommended INR of 2 to 3. However, the published data are sparse, heterogeneous, and primarily reported from clinical trials. More studies evaluating clinical outcomes in relation to INR are needed, especially in a real-world setting.
引用
收藏
页码:1938 / 1945
页数:8
相关论文
共 50 条
  • [21] Effect of Warfarin on Outcomes in Septuagenarian Patients With Atrial Fibrillation
    Roy, Brita
    Desai, Ravi V.
    Mujib, Marjan
    Epstein, Andrew E.
    Zhang, Yan
    Guichard, Jason
    Jones, Linda G.
    Feller, Margaret A.
    Ahmed, Mustafa I.
    Aban, Inmaculada B.
    Love, Thomas E.
    Levesque, Raynald
    White, Michel
    Aronow, Wilbert S.
    Fonarow, Gregg C.
    Ahmed, Ali
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (03): : 370 - 377
  • [22] Warfarin and Stroke Outcomes in Hemodialysis Patients with Atrial Fibrillation
    Genovesi, Simonetta
    Santoro, Antonio
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10): : 2090 - 2092
  • [23] Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding
    Elliott, Meghan J.
    Zimmerman, Deborah
    Holden, Rachel M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (03) : 433 - 440
  • [24] Anticoagulation for atrial fibrillation after intracranial hemorrhage A systematic review
    Hawkes, Maximiliano A.
    Rabinstein, Alejandro A.
    NEUROLOGY-CLINICAL PRACTICE, 2018, 8 (01) : 48 - 57
  • [25] Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review
    Pugh, Dan
    Pugh, Jack
    Mead, Gillian E.
    AGE AND AGEING, 2011, 40 (06) : 675 - 683
  • [26] Disparities in Anticoagulation for Atrial Fibrillation: A Systematic Review of Recent Literature
    Daly, Danielle
    Wasfy, Jason
    CIRCULATION, 2021, 144
  • [27] Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
    Liang, Hai-Feng
    Du, Xin
    Zhou, Ying-Chun
    Yang, Xiao-Yi
    Xia, Shi-Jun
    Dong, Jian-Zeng
    Lip, Gregory Y. H.
    Ma, Chang-Sheng
    MEDICAL SCIENCE MONITOR, 2019, 25 : 4691 - 4698
  • [28] Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Brooks, Maria M.
    Chin, Paul K.
    Saba, Samir
    CIRCULATION, 2016, 134
  • [29] Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Brooks, Maria M.
    Chin, Paul K.
    Saba, Samir
    CIRCULATION, 2016, 134
  • [30] The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
    Singer, Daniel E.
    Chang, Yuchiao
    Fang, Margaret C.
    Borowsky, Leila H.
    Pomernacki, Niela K.
    Udaltsova, Natalla
    Go, Alan S.
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (05) : 297 - U16